Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
study id #: NCT03153319
condition: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
status: Recruiting
purpose:Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
intervention: Adalimumab Injection [Humira], Saline Solution for Injection
results: https://clinicaltrials.gov/ct2/show/results/NCT03153319
last updated: February 26, 2022
-
Evaluation of the Long-Term Treatment Effects of Intravenous Idursulfase in Patients With Mucopolysaccharidosis II (...Mucopolysaccharidosis II (MPS II; Hunter...
-
Spectrum of MPS 1 H/S Diseasehttps://www.onempsvoice.com/wp-content/u...
-
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th ...REGENXBIO Inc. (Nasdaq: RGNX) today anno...
-
Hyo-Mental Angle and Distance: An Important Adjunct in Airway Assessment of Adult MucopolysaccharidosisMucopolysaccharidosis (MPS) is a rare co...
-
Carpal Tunnel Syndrome and Finger Deformities in Children With Mucopolysaccharidoses and Mucolipidoses: A Retrospect...This single-centre retrospective study r...
-
Mucopolysaccharidosis (MPS)https://slideplayer.com/slide/17257432/...
-
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting...Denali Therapeutics Inc., a biopharmaceu...